Beauty Health Co. Elects New Directors, CEO Gets New Employment Agreement
Ticker: SKIN · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1818093
| Field | Detail |
|---|---|
| Company | Beauty Health Co (SKIN) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, management-changes
TL;DR
Beauty Health Co. shakes up board with two new directors and inks new deal for CEO Anja van der Vliet.
AI Summary
On April 8, 2024, Beauty Health Co. announced changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Ms. Jessica L. Barouch and Mr. Michael P. D. O'Hanlon, to its Board of Directors. Additionally, the company entered into a new employment agreement with its Chief Executive Officer, Ms. Anja van der Vliet, effective April 8, 2024.
Why It Matters
Changes in board composition and executive employment terms can signal shifts in company strategy or leadership focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive agreements can introduce uncertainty regarding future strategy and leadership stability.
Key Players & Entities
- Beauty Health Co. (company) — Registrant
- Jessica L. Barouch (person) — Newly Elected Director
- Michael P. D. O'Hanlon (person) — Newly Elected Director
- Anja van der Vliet (person) — Chief Executive Officer
- April 8, 2024 (date) — Effective Date of Changes
FAQ
Who were the new directors elected to Beauty Health Co.'s Board of Directors?
Ms. Jessica L. Barouch and Mr. Michael P. D. O'Hanlon were elected as new directors.
When did the changes in directors and executive compensation become effective?
The changes were effective as of April 8, 2024.
What is the name of the Chief Executive Officer of Beauty Health Co.?
The Chief Executive Officer is Ms. Anja van der Vliet.
What type of report did Beauty Health Co. file on April 9, 2024?
Beauty Health Co. filed a Form 8-K, a Current Report.
What is the principal executive office address for Beauty Health Co.?
The principal executive offices are located at 2165 Spring Street, Long Beach, CA 90806.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-04-09 16:20:13
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Marke
Filing Documents
- skin-20240408.htm (8-K) — 27KB
- 0001628280-24-015457.txt ( ) — 179KB
- skin-20240408.xsd (EX-101.SCH) — 2KB
- skin-20240408_def.xml (EX-101.DEF) — 15KB
- skin-20240408_lab.xml (EX-101.LAB) — 26KB
- skin-20240408_pre.xml (EX-101.PRE) — 15KB
- skin-20240408_htm.xml (XML) — 3KB
From the Filing
skin-20240408 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 The Beauty Health Company (Exact name of registrant as specified in its charter) Delaware 001-39565 85-1908962 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2165 Spring Street Long Beach , CA (Address of principal executive offices) 90806 (Zip Code) ( 800 ) 603-4996 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Operating Officer Departure On April 8, 2024, The Beauty Health Company (the "Company") and Brad Hauser mutually agreed to terminate Mr. Hauser's employment as Chief Operating Officer of the Company without cause, effective as of April 9, 2024. Mr. Hauser will remain with the Company in an advisory role until no later than June 30, 2024. Mr. Hauser's separation is not a result of any disagreement with the Company on any matter relating to the Company's financial reporting, operations, policies or practices. The Company intends to file a separate, subsequent Current Report on Form 8-K within four business days after the Company and Mr. Hauser enter into a definitive separation agreement with respect to Mr. Hauser's separation as Chief Operating Officer of the Company. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 9, 2024 The Beauty Health Company By: /s/ Michael Monahan Name: Michael Monahan Title: Chief Financial Officer